Pipeline
SQUADRA Pipeline
-
00
Holding
SQUADRA Network
-
01
Holding
DD
7 Solutions -
02
Holding
Pre-Seed
-
04
Holding
Seed
-
05
Holding
Portfolioco Spin-Off
-
06
Portfolioco
Series A
-
07
Portfolioco
Series B
-
00
Holding
SQUADRA Network
-
01
Holding
DD
7 Solutions -
02
Holding
Pre-Seed
-
04
Holding
Seed
-
05
Holding
Portfolioco Spin-Off
-
06
Portfolioco
Series A
-
07
Portfolioco
Series B
Antonello Fazio
Project Lead
Seed Stage
Scott Parazynski, MD
Project Lead
Pre-Seed Stage
Eng. Maria Aboytes
Project Lead
Pre-Seed Stage
2022 Portfolio
Pre-Seed &
Seed Stage
Antonello Fazio
Project Lead
Seed Stage
PROBLEM
The current invasive surgical treatment for ascending aortic aneurisms is very high risk with up to 80% mortality rates.
INNOVATIVE SOLUTION
Developing the first non-invasive device for the treatment of ascending aorta aneurisms and dissections, which is a deadly heart condition.
INVESTMENT OPPORTUNITY
Market size: $1.7B
Non-dilutive funding approved $1M
TARGET EXIT STRATEGY
M&A in 2027: $350M
Scott Parazynski, MD
Project Lead
Pre-Seed Stage
PROBLEM
Sensitive and specific diagnostic, imaging and therapeutic options for deadly cancers like glioblastoma do not exist.
INNOVATIVE SOLUTION
Highly targeted, stable aptamers allow us to bind glioblastoma stem cells, and will lead to screening blood tests, theragnostics and payload delivery for better outcomes.
INVESTMENT OPPORTUNITY
Market size: $4.2B (by 2028)
TARGET EXIT STRATEGY
M&A in 2028: $450M
Eng. Maria Aboytes
Project Lead
Pre-Seed Stage
PROBLEM
60% post ischemic stroke treatment disability.
INNOVATIVE SOLUTION
Developing the first device to treat ischemic stroke in first pass (time saving = reduced mortality/disability rates) and more effectively (targeting soft, medium, and hard clots that currently are an unmet need).
INVESTMENT OPPORTUNITY
Market size: $1B (by 2028)
TARGET EXIT STRATEGY
M&A in 2027: $350M
Connect with us
on LinkedIn.
Visit our profile
What's new at SQUADRA?
Get the latest news about
medtech and investments.
